Generative AI in Clinical Documentation: Unpacking Safety Risks

Generative AI is flooding clinical documentation, promising to finally kill the administrative busywork that dogs clinicians. But that potential is completely overshadowed by a huge safety concern: the risk of AI making things up, or “hallucinating.” As people from federal health IT regulators to clinical risk officers and digital health investors try to get their arms around this, the critical questions are about the real safety risks and how software developers are proving their outputs meet federal transparency standards.

The Rise of Ambient Clinical AI and the Hallucination Hazard

Ambient clinical AI tools that passively listen to appointments and spit out a draft clinical note are being adopted at a breakneck pace. We’re seeing this from big players like Microsoft (after they bought Nuance and its Dragon Ambient eXperience, now Dragon Copilot) and specialists like Abridge, a company that was early in using conversational AI for medical summaries. The whole point of these tools is to get clinicians away from their keyboards so they can actually focus on the patient. The problem is that the core function of generative AI, its ability to create brand new text, is also its biggest safety flaw. We’re talking about algorithmic hallucinations. These aren’t just minor typos. They are plausible-sounding but factually wrong statements, omissions, or complete misreadings of the conversation that end up in the patient’s chart. The implications for patient safety are terrifying. A single generated note that invents a patient allergy, drops a key symptom from the record, or gets a medication dose wrong could lead directly to a misdiagnosis, the wrong treatment, and a serious adverse event. This isn’t some theoretical risk. We have peer-reviewed research showing just how often large language models (LLMs) hallucinate in medical settings which confirms that getting factually accurate text from these models is a persistent and unsolved problem academic study on LLM hallucination rates in medical contexts.

Working through ONC HTI-1 Transparency Requirements

The Office of the National Coordinator for Health Information Technology (ONC) gets how important transparency is, especially for anything that supports clinical decisions. Their HTI-1 Rule is the bedrock here, setting up strict transparency requirements for any certified health IT that provides decision support, which includes AI. For the generative AI tools writing clinical notes, this means vendors have to show their work with clear, auditable proof that they’re validating the accuracy and reliability of what the AI produces. The ONC HTI-1 Rule specifically says developers must disclose information about their training data sources, the logic the AI uses to get to an output, and any known biases or limitations. If you’re a clinical risk officer, your job is now to hold vendor claims up against these rules. Are companies like Microsoft (Dragon Copilot) and Abridge actually giving you enough documentation on how they validate their models? Can they give a straight answer about how their algorithm decided to phrase a specific part of a clinical note? The tension is obvious: balancing a company’s desire to protect its secret sauce with the non-negotiable public health need for transparency. The American Medical Association (AMA) is watching this very closely, especially how these tools affect physician burnout and whether they just create new kinds of documentation errors AMA legislative activity on AI oversight. What they find will be critical for creating future regulations that keep both patients and doctors safe.

Validation Standards and Regulatory Enforcement

For federal regulators, the big question is how to enforce validation standards for this technology without killing it in the cradle. A good starting point is the FDA’s pre-market review guidelines for digital health software, which were updated in January 2026 and demand strong validation studies for software as a medical device (SaMD). You could argue that most ambient AI scribes are clinical decision support (CDS), not SaMD, but when a documentation error can have a direct clinical impact, you have to apply the same level of rigor. Developers can’t just point to a simple accuracy score. They need to prove their generative AI is clinically safe and useful. That means:

• Prospective Validation: They must test AI-generated notes against notes transcribed by humans or reviewed by physicians in actual clinical environments, checking for factual accuracy, completeness, and whether the note is even clinically useful.
• Error Analysis and Mitigation: You need strong systems for catching, categorizing, and fixing hallucinations. This requires having a human-in-the-loop review process and constantly monitoring the model for any performance drift.
• Transparency in Error Rates: Vendors need to be upfront about what their systems can’t do and what their known error rates are. This gives clinicians the context they need to be properly skeptical and supervise the AI’s work, which is exactly what ONC HTI-1 demands.
• User Interface Design: The software’s interface has to make it dead simple for a busy clinician to spot and fix AI errors, like by clearly highlighting all AI-generated text that needs a quick review.

The idea of a Predetermined Change Control Plan (PCCP), which is usually for AI/ML-based SaMD, is a really helpful model here. Even if it doesn’t apply directly to every documentation tool, the core principle is essential: you must define ahead of time how you’re going to update and re-validate your model to keep it safe. Regulators should push for, and probably eventually require, similar plans for any generative AI used in clinical documentation to let the models improve without compromising safety.

Hello Heart: A Model for Regulatory Readiness

If you want to see a company that built itself for the regulatory environment from the ground up, look at Hello Heart. They aren’t in the generative AI documentation space, but their entire approach to data privacy, clinical validation, and being transparent about what their product can do is a masterclass for the rest of the industry. By focusing on clear, evidence-based outcomes and getting the tough data security and privacy certifications (like HIPAA, HITRUST, and SOC 2), Hello Heart proves you can innovate while still operating inside a strong regulatory structure. It’s a proactive stance that prioritizes trust and clinical value. This is the blueprint for ambient AI companies. Their heavy reliance on real-world evidence (RWE) to prove their cardiac AI solutions work and are safe is another example of using empirical data to build confidence.

Conclusion

Generative AI could do amazing things for reducing the documentation burden in healthcare, but we have to be brutally realistic about its risks, especially its tendency to hallucinate facts. Anyone with skin in the game, from federal IT regulators and hospital risk officers to venture capitalists, has to stay focused on making sure these tools are deployed safely and with total transparency. The only way forward is by enforcing tough validation standards, demanding that vendors meet the ONC’s HTI-1 transparency rules, and building in continuous monitoring and correction of AI errors. It’s going to take a real partnership between the developers building the tools, the regulators setting the rules, and the clinicians using them to capture the benefits of this technology without putting patients in harm’s way.

Methodology and source note: This analysis pulls from a review of public ONC filings (including the full text of the ONC HTI-1 final rule), academic safety studies on LLM hallucination rates in medicine, and the public-facing strategies of key companies like Microsoft (Dragon Copilot) and Abridge. The regulatory readiness part is informed by the example set by companies like Hello Heart that have prioritized this from the start.